Jazz Pharmaceuticals reported strong Q2 earnings, outperforming sector expectations.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been recognized as a standout performer in Q2 earnings according to a recent industry report. The stock closed at US$230.25, marking a 0.16% increase for the day. However, over the past week, the stock has seen a decrease of 0.94%, and it has dropped 4.36% over the last month. Year-to-date, Jazz has gained 36.32%.
Advertisement
Jazz Pharmaceuticals PLC
JAZZ.US
JAZZ.US
Jazz Pharmaceuticals PLC
WealthAwesomeMarket cap
$15.32B
P/E
16.1x
52W high
$266.38
52W low
$128.80
1W change
-0.94%
Beta
0.37
Analyst Price Targets
Based on 22 analysts covering JAZZ · as of Oct 5, 2026
Wall Street analysts forecast JAZZ stock price to rise 24.7% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
C$294.27
+24.7% Upside
Current Price
C$236.04
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on JAZZ's historical volatility
30-Day Vol
26.3%
Annualized
90-Day Vol
27.6%
Annualized
Trend (90d)
-13.6%
Annualized drift
90d Mean
C$224.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$232.24 | C$212.09 – C$254.32 |
| 60 trading days | C$228.51 | C$200.97 – C$259.81 |
| 90 trading days | C$224.83 | C$192.12 – C$263.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Jazz Pharmaceuticals' performance following its recent earnings recognition.
Jazz Pharmaceuticals Last Close at US$230.25
The stock closed at US$230.25, reflecting a 0.16% increase in the last trading day.
Bull case
Jazz Pharmaceuticals' strong earnings and solid market position may boost investor confidence moving forward.
Bear case
Despite the current earnings strength, ongoing volatility in the pharmaceutical sector could pose risks for investors.
Jazz Pharmaceuticals Recognized as Q2 Earnings Outperformer
Advertisement
Jazz Pharmaceuticals has been highlighted as an earnings outperformer in Q2, based on a recent report focusing on the pharmaceutical sector. This recognition comes as the company maintains a solid market presence, boasting a profit margin of 20.4% and a return on equity (ROE) of 22.1%. The stock currently trades at US$230.25, which is 74% of its 52-week range of US$128.80 to US$266.38, showcasing its strong performance in a competitive landscape.
Stock Performance Metrics and Trading Volume
In the last trading session, Jazz Pharmaceuticals closed at US$230.25, with a 1-day increase of 0.16%. The trading volume for the day was 223,611 shares, which is 1.16 times the 20-day average volume of 731,005 shares. The stock has experienced a year-to-date gain of 36.32%, despite recent monthly declines of 4.36%. Notably, the stock is currently trading below its 50-day moving average of US$247.21, reflecting a decline of 6.9%, but above its 200-day moving average of US$211.91, indicating an 8.7% increase.
Future Outlook for Jazz Pharmaceuticals
With an average analyst target of US$294.27, suggesting a potential upside of 27.8%, investors are likely to remain optimistic about Jazz's future performance. The company’s price-to-earnings (P/E) ratio stands at 16.145, indicating a favorable valuation relative to its earnings. As Jazz continues to navigate the pharmaceutical sector, its ability to maintain strong earnings and manage market volatility will be crucial for sustaining investor confidence and achieving long-term growth.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
